Subscribe To
RXDX / Why Shares of Prometheus Biosciences Slumped This Week
RXDX News
By Zacks Investment Research
May 12, 2023
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal
By Zacks Investment Research
May 9, 2023
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
Prometheus Biosciences, Inc. (RXDX) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.92. This com more_horizontal
By The Motley Fool
April 20, 2023
Why Prometheus Biosciences Stock Is Skyrocketing This Week
Merck plans to acquire Prometheus for $10.8 billion in an all-cash deal. The deal will add Prometheus' lead candidate, immunology drug PRA023, to Merc more_horizontal
By Pulse2
April 19, 2023
Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion
Merck (known as MSD outside the United States and Canada) and Prometheus Biosciences recently announced that the companies have entered into a definit more_horizontal
By Zacks Investment Research
April 18, 2023
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?
Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revision more_horizontal
By The Motley Fool
April 17, 2023
Why Shares of Prometheus Biosciences Are Soaring Monday
Prometheus' lead therapy treats ulcerative colitis and a variety of autoimmune disorders. Merck is looking to supplement its immunology portfolio. more_horizontal
By Invezz
April 17, 2023
Biotech stock Prometheus Biosciences opened 70% up today: here's why
Prometheus Biosciences Inc (NASDAQ: RXDX) opened about 70% up on Monday after Merck & Co Inc (NYSE: MRK) said it will buy the biotechnology company fo more_horizontal
By Zacks Investment Research
April 17, 2023
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' more_horizontal